Sodium Channel Antagonists

Cytochrome P450 2B6 Inhibitors

Cytochrome P450 2C19 Inhibitors

Cytochrome P450 3A4 Inducers

Cytochrome P450 2C8 Inducers

Cytochrome P450 2B6 Inducers

Cytochrome P450 3A Inhibitors

GABA A Receptor Positive Modulators

Epilepsies, Partial

<section class="Section" data-sectioncode="34089-3"><a name="s_1100"></a><a name="section-11"></a><h1>11 DESCRIPTION</h1>The chemical name of XCOPRI (cenobamate) is [(1R)-1-(2-Chlorophenyl)-2-(tetrazol-2-yl) ethyl] carbamate. Its molecular formula is C10H10ClN5O2 and its molecular weight is 267.67 g/mol. The chemical structure is:<img alt="Chemical Structure" src="cenobamate-01.jpg"/>Cenobamate is a white to off-white crystalline powder. It is slightly soluble in aqueous solutions (water 1.7 mg/mL) and has higher solubility in organic solvents like ethanol (209.4 mg/mL).XCOPRI tablets are for oral administration and contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate and film coating agents specified below:12.5 mg tablets: Not applicable, since 12.5 mg tablets are uncoated. 25 mg and 100 mg tablets: FD&amp;C Blue# 2/indigo carmine aluminum lake, iron oxide red, iron oxide yellow, polyethylene glycol 3350, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide. 50 mg tablets: iron oxide yellow, polyethylene glycol 3350, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide. 150 mg and 200 mg tablets: iron oxide red, iron oxide yellow, polyethylene glycol 3350, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.</section>

Xcopri

cenobamate

cenobamate 50 MG Oral Tablet

cenobamate 50 MG Oral Tablet [Xcopri]

cenobamate 100 MG Oral Tablet

cenobamate 100 MG Oral Tablet [Xcopri]

cenobamate 150 MG Oral Tablet

cenobamate 150 MG Oral Tablet [Xcopri]

cenobamate 200 MG Oral Tablet

cenobamate 200 MG Oral Tablet [Xcopri]

cenobamate 12.5 MG Oral Tablet

cenobamate 25 MG Oral Tablet

cenobamate 12.5 MG Oral Tablet [Xcopri]

cenobamate 25 MG Oral Tablet [Xcopri]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form 

Reimbursement Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

SK Life Science Navigator Enrollment Form

SK Life Science Navigator Enrollment Form - Online 

Patient Authorization For SK Life Science Navigator Enrollment Form 

Enroll in Patient Savings Program 

Enroll in a Bridge Program 

Patient Assistance Program Application 

Xcopri Trial Offer 

Other HCP Resources 

Other HCP Resouces: Video 

About Xcopri 

Side Effects 

Patient Stories 

FAQs: Partial Onset Seizures 

Patient Resources 

Instructions For Use: Partial Onset Seizures 

Patient Brochure 

Caregiver Brochure

STEPS Discussion Guide 